Publication Name	World Journal of Clinical Oncology
Manuscript ID	20981
Country	Italy

Received	2015-06-27 09:11
Peer-Review Started	2015-06-30 09:51
To Make the First Decision	2015-09-17 13:27
Return for Revision	2015-09-25 11:30
Revised	2015-11-20 00:52
Second Decision	2016-01-27 13:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-02-16 09:42
Articles in Press	2016-02-16 09:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-24 16:21
Publish the Manuscript Online	2016-04-07 11:01

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biochemistry & Molecular Biology
Manuscript Type	Editorial
Article Title	Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
Manuscript Source	Invited Manuscript
All Author List	Irene Marchesi and Luigi Bagella
Funding Agency and Grant Number
Corresponding Author	Luigi Bagella, PhD, Department of Biomedical Sciences, Division of Biochemistry, University of Sassari, Viale S. Pietro 43/b, 07100 Sassari, Italy. lbagella@uniss.it
Key Words	Enhancer of Zeste Homolog 2; Polycomb group proteins; Histone methyltransferase; Enhancer of Zeste Homolog 2 inhibitors; Anticancer drugs; Cancer therapy; Epigenetics
Core Tip	Epigenetics modifications are key players in differentiation programs and are frequently altered in cancer. Since chromatin changes can be reversed with specific drugs, in the last years several studies explored the possibility to target epigenetics alteration as a new strategy for cancer treatment. This editorial focuses on Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb repressive complex 2 in cancer, analyzing different roles of this protein in various cancers. Several different classes of EZH2 inhibitors are also highlighted, giving distinct thoughtfulness to small molecules that are now under consideration as potential candidates for cancer treatment alone or in combination with other drugs.
Publish Date	2016-04-07 11:01
Citation	Marchesi I, Bagella L. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol 2016; 7(2): 135-148
URL	http://www.wjgnet.com/2218-4333/full/v7/i2/135.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i2.135

Full Article (PDF)	WJCO-7-135.pdf
Full Article (Word)	WJCO-7-135.doc
Manuscript File	20981-Review.doc
Answering Reviewers	20981-Answering reviewers.pdf
Audio Core Tip	20981-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20981-Conflict-of-interest statement.pdf
Copyright License Agreement	20981-Copyright assignment.pdf
Peer-review Report	20981-Peer-review(s).pdf
Scientific Misconduct Check	20981-Scientific misconduct check.pdf
Scientific Editor Work List	20981-Scientific editor work list.pdf